ClinicalTrials.gov
public full text
Public Domain
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases
The goal of this study is to evaluate the safety and effi cacy of CD19 CAR T cells in the treatment of Refractory Autoimmune Diseases.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases#1152826
- KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis#876724
- Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases#1029969
- Human CD1c-autoreactive T cells recognise <i>Mycobacterium tuberculosis</i> –infected antigen-presenting cells and display cytotoxic effector programmes#273220
- A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma#880565
Record · ID 853824
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive